Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Disc Medicine, Inc. (NASDAQ:IRON) has received an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $104.80.

IRON has been the topic of several recent research reports. Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. BMO Capital Markets cut their target price on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Tuesday, February 17th. Wedbush reduced their price target on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Morgan Stanley set a $75.00 target price on Disc Medicine in a research note on Tuesday, February 17th. Finally, UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 40,000 shares of Disc Medicine stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $93.05, for a total value of $3,722,000.00. Following the completion of the sale, the chief executive officer directly owned 171,828 shares of the company’s stock, valued at approximately $15,988,595.40. The trade was a 18.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jean M. Franchi sold 7,081 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $65.47, for a total value of $463,593.07. Following the completion of the transaction, the chief financial officer owned 71,343 shares of the company’s stock, valued at $4,670,826.21. This trade represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 292,492 shares of company stock valued at $25,423,925. 3.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Hedge funds have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Disc Medicine during the 4th quarter valued at $33,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Disc Medicine in the third quarter valued at about $38,000. CWM LLC grew its position in Disc Medicine by 213.5% in the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after acquiring an additional 711 shares in the last quarter. KBC Group NV purchased a new stake in Disc Medicine during the 4th quarter worth $80,000. Finally, Avanza Fonder AB lifted its stake in shares of Disc Medicine by 54.0% in the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after acquiring an additional 585 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Stock Performance

NASDAQ IRON opened at $61.10 on Thursday. The business has a 50 day moving average price of $73.48 and a 200 day moving average price of $75.59. The company has a market capitalization of $2.31 billion, a P/E ratio of -10.20 and a beta of 0.87. Disc Medicine has a 1-year low of $30.82 and a 1-year high of $99.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 23.45.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, topping analysts’ consensus estimates of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analysts’ expectations of $0.15 million. Sell-side analysts expect that Disc Medicine will post -4.07 EPS for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.